OptimizeRx Q3 revenue $21.3M (+30% YoY); GAAP net loss $(9.1)M; guides FY24 rev $88-$92M

OptimizeRx Corp

2024-Q3 EPS reported -$1.10 revenue$59,811,000

Q3 revenue $21.3M, up 30% YoY from $16.3M; gross profit $13.4M (+37%); margin 63%.
GAAP net loss $(9.1)M ($(0.50)/share) vs $(2.9)M loss last year; non-GAAP net income $2.3M ($0.12/sh) vs $1.6M.
Adjusted EBITDA $2.7M, up from $0.9M; cash and equivalents $16.1M; paid down $2M on term loan post-quarter.
Updated FY2024 guidance: revenue $88-$92M, Adjusted EBITDA $8-$10M; won 5 DAAP deals in Q3.
Net revenue retention 127% (rolling 12-month); top-20 pharma customers revenue per avg $2.8M vs $1.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.